Percentage of patients with axSpA with radiographic sacroiliitis fulfilling both sets of criteria, either criteria set or neither
| mNY+ASAS+ | mNY+ASAS- | mNY- ASAS+ | mNY- ASAS- | Total mNY+* | Total ASAS+† | |
| ASAS (N=114) | 86% (98) | 2% (3) | 10% (11) | 2% (2) | 89% (101) | 96% (109) |
| GESPIC (N=96) | 81% (78) | 12% (11) | 6% (6) | 1% (1) | 93% (89) | 88% (84) |
| Esperanza (N=109) | 97% (106) | 3% (3) | NA‡ | NA‡ | 100% (109) | – |
| OASIS (N=211) | 95% (201) | 5% (10) | NA‡ | NA‡ | 100% (211) | – |
| Reuma.pt (N=1320) | 88% (1156) | 7% (93) | 4% (55) | 1% (16) | 95% (1249) | 92% (1211) |
| SCQM (N=1806) | 89% (1612) | 8% (148) | 2% (40) | 0.3% (6) | 97% (1760) | 91% (1652) |
| SPACE (N=92) | 84% (77) | 0% (0) | 16% (15) | 0% (0) | 84% (77) | 100% (92) |
| UCSF (N=293) | 95% (279) | 2.5% (7) | 2.5% (7) | 0% (0) | 98% (286) | 98% (286) |
| Total (N=4041) | 89% (3607) | 7% (275) | 3% (134) | 1% (25) | 96% (3882) | – |
*The total percentage of patients who fulfil the mNY criteria per cohort and in total.
†The total percentage of patients who fulfil the ASAS r-axSpA criteria per cohort and in total.
‡Specific information on the individual items of the mNY clinical criteria was unavailable, it was therefore not possible to accurately calculate the number of patients fulfilling the mNY in the subgroup fulfilling the ASAS r‑axSpA criteria.
ASAS, Assessment of SpondyloArthritis international Society cohort; Esperanza, Spanish national health programme for early SpA; GESPIC, GErman SPondyloarthritis Inception Cohort; NA, not available; OASIS, Outcome in Ankylosing Spondylitis International Study; Reuma.pt, Portuguese Register for Rheumatic Diseases; SCQM, Swiss Clinical Quality Managementcohort; SPACE, SPondyloArthritis Caught Early cohort; UCSF, University of California San Francisco axSpA cohort; axSpA, axial spondyloarthritis; mNY, modified New York; r-axSpA, radiographic axial spondyloarthritis.